OptimizeRX price target raised to $23 from $20 at Citizens

Investing.com - Citizens has raised its price target on OptimizeRX (NASDAQ:OPRX) to $23.00 from $20.00, while maintaining a Market Outperform rating on the stock. The company has shown remarkable momentum, with a 276% year-to-date return and maintains a "GOOD" financial health score according to InvestingPro analysis.

The price target increase represents a multiple of 23 times Citizens’ revised 2026 estimated EBITDA, compared to the previous target which was based on 23 times 2025 estimated EBITDA.

Citizens noted that OptimizeRX recently traded at approximately 22.5 times the firm’s 2025 EBITDA estimate, indicating the new target is in line with current valuation trends.

The research firm has also increased its 2026 revenue and EBITDA estimates for OptimizeRX, citing expectations for continued momentum through the second half of 2025.

Citizens expressed a positive outlook on the growth of OptimizeRX’s subscription-based data revenues and highlighted potential margin expansion opportunities due to what it describes as the company’s "highly scalable platform."

In other recent news, OptimizeRx Corp has reported impressive financial results for the second quarter of 2025. The company achieved revenue of $29.2 million, marking a 55% increase compared to the previous year and surpassing analysts’ projections of $22.3 million. Additionally, OptimizeRx delivered an earnings per share (EPS) of $0.24, significantly exceeding the forecasted $0.02, which represents a 1100% surprise. Following these strong earnings, JMP Securities raised its price target for OptimizeRx from $14 to $20, maintaining a Market Outperform rating.

In a strategic move to drive its growth strategy, OptimizeRx announced a leadership reorganization, appointing Ed Stelmakh as Chief Financial & Strategic Officer. This change is part of the company’s "Rule of 40" strategy, aimed at balancing growth with profitability over the next few years. These developments indicate a period of positive momentum for OptimizeRx, as the company continues to exceed financial expectations and strengthen its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.